Prevalence of Frailty in Patients With a Cardiovascular Disease and Correlations With Markers of Exercise
In the first part of this study the prevalence of frailty in patients with cardiovascular disease will be examined. Frailty is defined as a progressive age-related decline in physiological systems that results in decreased reserves of intrinsic capacity, which confers extreme vulnerability to stressors. Patients (≥65 years, men and women) suffering from heart failure or undergoing a coronary artery bypass grafing (CABG) or percutaneous coronary intervention (PCI) will be included. Based on the phenotype of Fried, frailty will be examined in the physical domain. Moreover, the nutritional, social, psychological and cognitive domain of frailty will be examined. This will result in a total score of 0 (no frailty) to 24 (severe frailty), divided into four categories: no frailty (score 0-6), minor frailty (score 7-12), moderate frailty (score 13-18) or severe frailty (score 18-24).
Besides this frailty protocol, a few other measurements will be completed to collect additional information about the functioning of the patient.
At discharge from the hospital, some of these patients will start with a cardiac rehabilitation program. To define the exercise intensity of this program, patients will perform a maximal exercise test (CPET). In the second part of this study, correlations will be examined between markers of frailty and markers of exercise from the CPET (e.g. maximal heart rate, maximal oxygen uptake).
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Limburg
-
Hasselt, Limburg, Bélgica, 3500
- Jessa Hospital Campus Virga Jesse
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
Men and women with an age of at least 65 years at the start of the study; Staying in Jessa Hospital for PCI, CABG or heart failure
Exclusion Criteria:
A persistently unstable clinical condition at baseline visit (angina, advanced conduction disturbances, threatening ventricular arrhythmias, acute heart failure, clinical condition requiring interventions such as acute renal failure, Hb <9,0 mg/dl, presence of end-stage disease or the lack of informed consent to study participation)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Otro
- Perspectivas temporales: Transversal
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Level of (in)dependence via the Katz scale
Periodo de tiempo: At baseline
|
Evaluation of the level of (in)dependence in activities of daily life via a 4-point scale (1-4)
|
At baseline
|
|
Nutritional status via the Mini Nutritional Assessment (MNA)
Periodo de tiempo: At baseline
|
Examination of the nutritional status of the patient via a questionnaire (30 points)
|
At baseline
|
|
Level of physical activity via the International Physical Activity Questionnaire (IPAQ)
Periodo de tiempo: At baseline
|
Examination of the level of physical activity of the patient via a questionnaire
|
At baseline
|
|
Cognitive status via the Mini Mental State Examination (MMSE)
Periodo de tiempo: At baseline
|
Examination of the cognitive status of the patient via a short screening (30 points)
|
At baseline
|
|
Psychological status via the Geriatric Depression Scale (GDS-15)
Periodo de tiempo: At baseline
|
Examination of the presence/absence of a depressive mood via a questionnaire (15 questions/15 points)
|
At baseline
|
|
Concern about falling via the Falls Efficacy Scale (FES-I)
Periodo de tiempo: At baseline
|
Examination of the level of concern about falling during social and physical activities via a questionnaire (16 questions/ 64 points)
|
At baseline
|
|
Weight loss via the evaluation of body weight
Periodo de tiempo: At baseline
|
Evaluation of involuntary loss of body weight in the previous months
|
At baseline
|
|
Gait speed via the 4.6 meter walking test
Periodo de tiempo: At baseline
|
Examination of the walking speed of the patient
|
At baseline
|
|
Evaluation of handgrip strength
Periodo de tiempo: At baseline
|
Evaluation of the handgrip strength of the patient via handheld dynamometry
|
At baseline
|
|
Examination of mobility/balance/muscle strength/risk of falling via the Timed Up and Go Test (TUG)
Periodo de tiempo: At baseline
|
The Timed Up and Go Test measures the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
By combining this test with a motor or cognitive dual task, the risk of falling of the patient will be examined.
|
At baseline
|
|
Comorbidities via the record of medication use
Periodo de tiempo: At baseline
|
Record of cardiac and other medications
|
At baseline
|
|
Evaluation of lower limb strength
Periodo de tiempo: At baseline
|
Evaluation of lower limb strength of the patient via Microfet measurements
|
At baseline
|
|
Evaluation of functional lower limb strength
Periodo de tiempo: At baseline
|
Evaluation of functional lower limb strength of the patient via the Timed Chair Stand Test
|
At baseline
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Correlations between frailty (via the primary frailty outcome measures) and exercise parameters (via the maximal exercise test (CPET)
Periodo de tiempo: At the start of the cardiac rehabilitation program
|
Evaluation of correlations between frailty characteristics (from the primary outcome measures) and exercise parameters from a maximal exercise test (CPET) (performed at the start of a cardiac rehabilitation program).
|
At the start of the cardiac rehabilitation program
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- FrCR
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .